Surmodics Past Earnings Performance
Past criteria checks 3/6
Surmodics's earnings have been declining at an average annual rate of -38.2%, while the Medical Equipment industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 7% per year. Surmodics's return on equity is 10.9%, and it has net margins of 9.4%.
Key information
-38.2%
Earnings growth rate
-38.4%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 7.0% |
| Return on equity | 10.9% |
| Net Margin | 9.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
May 02
We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M
Jul 27Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)
Jul 22Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 03Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why
Feb 04Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?
Dec 24Estimating The Fair Value Of Surmodics, Inc. (NASDAQ:SRDX)
Aug 13When Should You Buy Surmodics, Inc. (NASDAQ:SRDX)?
Jun 09Is Now The Time To Put Surmodics (NASDAQ:SRDX) On Your Watchlist?
May 10Surmodics EPS misses by $0.01, beats on revenue
Apr 28How Much Are Surmodics, Inc. (NASDAQ:SRDX) Insiders Taking Off The Table?
Feb 05
Revenue & Expenses BreakdownBeta
How Surmodics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 143 | 14 | 51 | 47 |
| 31 Dec 23 | 138 | 6 | 51 | 43 |
| 30 Sep 23 | 133 | -2 | 52 | 47 |
| 30 Jun 23 | 131 | -23 | 53 | 51 |
| 31 Mar 23 | 103 | -36 | 53 | 51 |
| 31 Dec 22 | 102 | -32 | 51 | 63 |
| 30 Sep 22 | 100 | -27 | 47 | 51 |
| 30 Jun 22 | 98 | -13 | 42 | 0 |
| 31 Mar 22 | 97 | -10 | 37 | 0 |
| 31 Dec 21 | 106 | 2 | 34 | 0 |
| 30 Sep 21 | 105 | 4 | 32 | 49 |
| 30 Jun 21 | 104 | 2 | 30 | -1 |
| 31 Mar 21 | 107 | 7 | 30 | 0 |
| 31 Dec 20 | 95 | 1 | 28 | 0 |
| 30 Sep 20 | 95 | 1 | 28 | 0 |
| 30 Jun 20 | 103 | 8 | 28 | 1 |
| 31 Mar 20 | 101 | 7 | 27 | 0 |
| 31 Dec 19 | 100 | 6 | 26 | 0 |
| 30 Sep 19 | 100 | 8 | 25 | 0 |
| 30 Jun 19 | 92 | 2 | 24 | 0 |
| 31 Mar 19 | 90 | -2 | 23 | 0 |
| 31 Dec 18 | 87 | -2 | 24 | 0 |
| 30 Sep 18 | 81 | -4 | 23 | 0 |
| 30 Jun 18 | 78 | -2 | 22 | 0 |
| 31 Mar 18 | 74 | 1 | 22 | 0 |
| 31 Dec 17 | 72 | 0 | 21 | 0 |
| 30 Sep 17 | 73 | 4 | 20 | 0 |
| 30 Jun 17 | 71 | 6 | 20 | 0 |
| 31 Mar 17 | 73 | 9 | 19 | 0 |
| 31 Dec 16 | 73 | 10 | 19 | 0 |
| 30 Sep 16 | 71 | 10 | 18 | 0 |
| 30 Jun 16 | 71 | 9 | 17 | 0 |
| 31 Mar 16 | 67 | 9 | 16 | 0 |
| 31 Dec 15 | 64 | 11 | 15 | 0 |
| 30 Sep 15 | 62 | 12 | 13 | 0 |
| 30 Jun 15 | 60 | 13 | 15 | 0 |
| 31 Mar 15 | 59 | 13 | 15 | 0 |
| 31 Dec 14 | 58 | 12 | 15 | 0 |
| 30 Sep 14 | 57 | 12 | 15 | 0 |
| 30 Jun 14 | 56 | 13 | 15 | 0 |
| 31 Mar 14 | 56 | 13 | 16 | 0 |
| 31 Dec 13 | 56 | 14 | 15 | 0 |
| 30 Sep 13 | 56 | 15 | 14 | 0 |
| 30 Jun 13 | 56 | 14 | 14 | 0 |
Quality Earnings: SRDX has high quality earnings.
Growing Profit Margin: SRDX became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SRDX has become profitable over the past 5 years, growing earnings by -38.2% per year.
Accelerating Growth: SRDX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SRDX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).
Return on Equity
High ROE: SRDX's Return on Equity (10.9%) is considered low.